Cargando…
Role of posaconazole in the treatment of oropharyngeal candidiasis
Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is...
Autores principales: | Ianas, Voichita, Matthias, Kathryn R, Klotz, Stephen A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108746/ https://www.ncbi.nlm.nih.gov/pubmed/21694893 |
Ejemplares similares
-
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis
por: Vazquez, Jose A
Publicado: (2007) -
Successful Treatment of Chronic Mucocutaneous Candidiasis Caused by Azole-Resistant Candida albicans with Posaconazole
por: Firinu, Davide, et al.
Publicado: (2011) -
Rethinking T cell immunity in oropharyngeal candidiasis
por: Pirofski, Liise-anne, et al.
Publicado: (2009) -
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
por: Vazquez, Jose A
Publicado: (2010) -
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
por: Rees, Hilary C., et al.
Publicado: (2013)